bu99008
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2015 (NCT02323217)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 11-carbon
Oral
No
Parenteral
No
Topical
No
Also known as
- 2-(4,5-dihydro-1h-imidazol-2-yl)-1-methyl-1h-indole
- bu99008
- bu99008
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02874820 | Early Phase 1 (Phase 1) | Jul 1, 2016 | GlaxoSmithKline, University of London |
| NCT02323217 | Early Phase 1 (Phase 1) | Jan 1, 2015 | GlaxoSmithKline, University of London |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 2 | 0 | 1 | 2015 |
| University of London | Academic/Hospital | 2 | 2 | 1 | 2015 |
2 organizations
Page 1 / 1